-
-
7 . Academic Journal
Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials
- 저자
- by Abbey, Ashkan; Abdulaeva, Elmira; Abraham, Prema; Adan Civera, Alfredo; Agostini, Hansjurgen, et al.
- 소스
- In The Lancet 19-25 February 2022 399(10326):729-740
-
7 . Periodical
Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials
- 저자
- by Heier, Jeffrey S; Khanani, Arshad M; Quezada Ruiz, Carlos; Basu, Karen; Ferrone, Philip J, et al.
- 소스
- The Lancet; February 2022, Vol. 399 Issue: 10326 p729-740, 12p